Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 itepekimab trial in adults with inadequately controlled chronic rhinosinusitis with nasal polyps
jRCT2031250095Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Sanofi. Primary endpoints: Change from baseline in endoscopic nasal polyp score and Change from baseline in nasal congestion score. Started Jul 2025; status: active, not recruiting.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT2031250095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250095.